Login
$AXGN
$55.38 -$0.55 (0.98%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Michael Dale Also a director
Chief Executive Officer
Title from the Form 4 dated Feb 26, 2026
66 Not stated Not stated $9,047,454
Lindsey Hartley
Chief Financial Officer
Not stated Since 2025
1 year
2021 $1,935,226
Marc Began
Executive Vice President, General Counsel and Chief Compliance Officer
Not stated Since 2023
3 years
Not stated $3,063,430
Erick DeVinney
Chief Innovation Officer
Not stated Since 2024
2 years
2007 $2,261,741
Jens Kemp
Chief Marketing Officer
Not stated Since 2023
3 years
Not stated $2,279,206
Doris Quackenbush
Sales VP
Title from the Form 4 dated May 7, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
5.1 years
from year joined
CEO also chairs the board
No
Paul Thomas
Director Age On board Independent Other public boards 2025 pay Source
Paul Thomas
70 2020
6 years
Independent None stated $242,055
Michael Dale
66 2024
2 years
Not independent BiomimedX, Inc. Paid as CEO
William Burke
57 2022
4 years
Independent None stated $224,990
John H. Johnson
68 2021
5 years
Independent Verastem Oncology $217,490
Alan M. Levine
58 2019
7 years
Independent None stated $217,490
Joseph Tyndall
57 2022
4 years
Independent None stated $209,990
Kathy Weiler
56 2023
3 years
Independent None stated $212,655
Amy Wendell
65 2016
10 years
Independent Hologic, Inc. $224,990

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 29, 2026
Global Nerve Foundation ("GNF")
a related party; certain executives of the Company are members of GNF's board of directors
$100,000
year ended December 31, 2025

Company contributions to GNF during 2025

Global Nerve Foundation ("GNF")
a related party; certain executives of the Company are members of GNF's board of directors
A total amount not to exceed $100,000
July 20, 2024 to December 31, 2031

Qualified Founding Partner Agreement with GNF granting the Company benefits related to GNF's programming and marketing, entered July 20, 2024 and terminating December 31, 2031; early termination requires payments of the next two scheduled payments

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support